Press "Enter" to skip to content

Rovalpituzumab Tesirine Program Ends After Poor Results in Lung Cancer Trial – Pulmonology Advisor

admin 0

Rovalpituzumab Tesirine Program Ends After Poor Results in Lung Cancer Trial  Pulmonology Advisor

AbbVie has announced that the research and development program for its investigational drug, Rova-T (rovalpituzumab tesirine), for advanced small-cell lung …

“lung cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *